ライフサイエンスコーパス: spinal cord injury

1 ng regeneration of injured axons relevant to spinal cord injury.

2 enerative failure of sensory axons following spinal cord injury.

3 worsened long-term outcomes after traumatic spinal cord injury.

4 to secondary injury mechanisms in traumatic spinal cord injury.

5 to enable improved functional outcome after spinal cord injury.

6 conditions, including multiple sclerosis and spinal cord injury.

7 deling, and functional recovery in mice with spinal cord injury.

8 accelerates regeneration of zebrafish after spinal cord injury.

9 ospinal circuits limits motor recovery after spinal cord injury.

10 changes in the atrophied cervical cord after spinal cord injury.

11 generative disease and CNS trauma, including spinal cord injury.

12 therapy is currently in clinical testing for spinal cord injury.

13 igration and functional repair in vivo after spinal cord injury.

14 tcomes in patients with tSCI or nontraumatic spinal cord injury.

15 ach appears to merit clinical translation in spinal cord injury.

16 nt future trials targeting acute and chronic spinal cord injury.

17 migration and reversed astroglial fate after spinal cord injury.

18 sticity that improves breathing in models of spinal cord injury.

19 ecruitment of spinal motor neurons following spinal cord injury.

20 ion in conditions such as cerebral palsy and spinal cord injury.

21 different degrees of paralysis and levels of spinal cord injury.

22 ote axonal regeneration and plasticity after spinal cord injury.

23 nassisted hindlimb locomotion after complete spinal cord injury.

24 owth-competent axons after sciatic nerve and spinal cord injury.

25 tor function in humans with paralysis due to spinal cord injury.

26 ectin-1 (Gal-1) promotes axonal growth after spinal cord injury.

27 asticity, and regeneration in the context of spinal cord injury.

28 for cardiovascular functional recovery after spinal cord injury.

29 a large prospective cohort study after human spinal cord injury.

30 for proof-of-concept studies in people with spinal cord injury.

31 te whether ED peptide has similar effects in spinal cord injury.

32 l pressure at 85 to 90mm Hg for a week after spinal cord injury.

33 vements and promotes axon regeneration after spinal cord injury.

34 overing from damage, such as after stroke or spinal cord injury.

35 tegy for ameliorating the adverse effects of spinal cord injury.

36 functional nervous system tissue after major spinal cord injury.

37 participant with quadriplegia from cervical spinal cord injury.

38 euronal survival and axon regeneration after spinal cord injury.

39 icospinal tract (CST), sprout after brain or spinal cord injury.

40 w flexor and extensor muscles after cervical spinal cord injury.

41 during the chronic phase following traumatic spinal cord injury.

42 ar dysfunction often occurs after high-level spinal cord injury.

43 wth of injured pathways in non-human primate spinal cord injury.

44 ian central nervous system trauma, including spinal cord injury.

45 esents the most common form of non-traumatic spinal cord injury.

46 is required for motor sensory recovery after spinal cord injury.

47 diovascular dysfunction following high-level spinal cord injury.

48 ion in multiple preclinical rodent models of spinal cord injury.

49 ented on the membranes of exosomes following spinal cord injury.

50 r patients with movement disorders following spinal cord injury.

51 ants in human patients with tetraplegia from spinal cord injury.

52 circuits mediates functional recovery after spinal cord injury.

53 and recovery of diaphragm function following spinal cord injury.

54 e limbs remain largely intact after complete spinal cord injury.

55 sons with diabetes, indwelling catheters, or spinal cord injury.

56 onship to long-term outcomes after traumatic spinal cord injury.

57 ercome loss of function after, for instance, spinal cord injury.

58 ute a novel therapy for spasticity following spinal cord injury.

59 to novel approaches to develop therapies for spinal cord injury.

60 generative diseases as well as for brain and spinal cord injuries.

61 pathways of protection in heart, brain, and spinal cord injuries.

62 uiding future studies of human subjects with spinal cord injuries.

63 al axons and restore forelimb function after spinal cord injury(1); however, the molecular mechanisms

64 5 (18.88) years) with subacute (ie, 1 month) spinal cord injury (25 patients with neuropathic pain, 1

65 hand dexterity increased in individuals with spinal cord injury after the I-wave protocol.

66 an reveal early inflammation associated with spinal cord injury after thoracic aortic ischemia-reperf

67 Rehabilitative exercise in humans with spinal cord injury aims to engage residual neural networ

68 al hydrolase (UCHL-1) biomarker of brain and spinal cord injuries and address the clinical need.

69 individuals with chronic incomplete cervical spinal cord injury and 17 uninjured participants.

70 or hurdle for functional recovery after both spinal cord injury and cortical stroke is the limited re

71 ired for the development of spasticity after spinal cord injury and during amyotrophic lateral sclero

72 oluntary and spinal reflex integration after spinal cord injury and in recovery of function are broad

73 -cost portable BMI for survivors of cervical spinal cord injury and investigated it as a means to sup

74 fficacy of this reagent in non-human primate spinal cord injury and its toxicological profile have no

75 e design and development of therapeutics for spinal cord injury and motor disorders.

76 driver of neuronal dysfunction in models of spinal cord injury and neurodegeneration, the contributi

77 ify their 'regenerative transcriptome' after spinal cord injury and NPC grafting.

78 To investigate what role C5b-9 plays in spinal cord injury and recovery, we generated littermate

79 prevalence of adverse events after traumatic spinal cord injury and to evaluate the effects on long-t

80 at motor evoked potentials size increased in spinal cord injury and uninjured participants after the

81 Vertebral LVs remodel extensively after spinal cord injury and VEGF-C-induced vertebral lymphang

82 tors has implications for signaling biology, spinal cord injury and, possibly, the evolution of the c

83 te subset is essential during scarring after spinal cord injury, and its arrest results in motor perf

84 ts to people with chronic tetraplegia due to spinal cord injury, and represents a major advance, with

85 city and promote axon regeneration following spinal cord injury, and results from preclinical studies

86 tered miRNA after severe, moderate, and mild spinal cord injury, and SHAM surgery, respectively.

87 rly complete recovery of neonatal mice after spinal cord injury, and suggest strategies that could be

88 ues in healthy animals or safety concerns in spinal cord injury animals.

89 In animals and people with incomplete spinal cord injury, appropriate operant conditioning of

90 antitative MRI metrics, obtained early after spinal cord injury, are predictive of clinical outcome.

91 This has important consequences following spinal cord injury, as neurons fail to regrow.

92 cell grafts support axonal growth following spinal cord injury, but a boundary forms between the imp

93 nd corticospinal growth in non-human primate spinal cord injury', by Wang et al. (doi:10.1093/brain/a

94 c remodeling and involves netrin-1 signaling.Spinal cord injury can induce synaptic reorganization an

95 use of their hands because of amputation or spinal cord injury can use prosthetic hands to restore t

96 th chronic tetraplegia, due to high-cervical spinal cord injury, can regain limb movements through co

97 udy participant was a 53-year-old man with a spinal cord injury (cervical level 4, American Spinal In

98 would represent a paradigm shift in the way spinal cord injury clinical trials could be conducted.

99 atent stem cell niche that is reactivated by spinal cord injury contributing new cells to the glial s

100 y protein Nogo-A applied to rats with severe spinal cord injury could prevent development of neurogen

101 Spinal cord injury creates physical and chemical barrier

102 llenged by recent findings in rodent model's spinal cord injury, demonstrating its neuroprotection an

103 into endogenous regenerative processes after spinal cord injury, demonstrating that Nrg1 signalling r

104 We present evidence that spinal cord injury directly causes increased risk for ba

105 neurons, a regeneration-incompetent central spinal cord injury does not.

106 ther potential biomarkers during a traumatic spinal cord injury event.

107 ility in individuals with traumatic brain or spinal cord injury, glaucoma and ischemia-reperfusion in

108 in and around the glial scar after mammalian spinal cord injury, have been suggested to be key inhibi

109 ered as a new therapeutic option to overcome spinal cord injury-immune depression syndrome and to dec

110 Mouse model of spinal cord injury-immune depression syndrome followed b

111 In patients with spinal cord injury, spinal cord injury-immune depression syndrome induces pn

112 We aimed to develop a new spinal cord injury-immune depression syndrome mouse mode

113 ng this pulmonary and systemic inflammation, spinal cord injury-immune depression syndrome was observ

114 C4ST1/Chst-11 accelerated regeneration after spinal cord injury in larval and adult zebrafish and kno

115 Using a mouse model of ischemic spinal cord injury in male and female mice, we show that

116 Spinal cord injury in mammals is thought to trigger scar

117 This model of spinal cord injury in mice mimics a clinical scenario re

118 receptor, promotes recovery after traumatic spinal cord injury in mice, a benefit achieved in part b

119 erface that alleviated gait deficits after a spinal cord injury in non-human primates.

120 onal sprouting and functional recovery after spinal cord injury in rodents.

121 This study investigates the response to spinal cord injury in the gray short-tailed opossum (Mon

122 new 'neural relays' across sites of complete spinal cord injury in vivo in rodents(1,2).

123 They used a rodent model of spinal cord injury, in which human neural progenitor cel

124 We propose that future drug trials for spinal cord injury include pressure and microdialysis mo

125 r organs, including the spleen, resulting in spinal cord injury-induced immunodeficiency.

126 cell death 1 molecules, improved survival of spinal cord injury infected mice and enhanced interferon

127 spinothalamic tract function-at 1 month post-spinal cord injury is associated with the emergence and

128 Spinal cord injury is characterized by acute cellular an

129 like cells are regulated in the aftermath of spinal cord injury is critical to design future manipula

130 Therapeutic development for spinal cord injury is hindered by the difficulty in cond

131 nic/intrinsic neural stem cells (NSCs) after spinal cord injury is severely compromised because the h

132 of rehabilitation strategies in humans with spinal cord injury is to strengthen transmission in spar

133 ection to spinal motor neurons from ischemic spinal cord injury (ISCI).

134 Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), examination.

135 s of time to anaesthetized mice sustaining a spinal cord injury leads to an instantaneous reduction o

136 Spinal cord injury leads to the disruption of neural cir

137 l sufficient to cause pneumonia dependent on spinal cord injury lesion level and investigated whether

138 etabolic alterations are observed in chronic spinal cord injury, likely reflecting neurodegeneration,

139 tion clinically.SIGNIFICANCE STATEMENT After spinal cord injury, loss of bladder control is common.

140 After complete spinal cord injury, mammals, including mice, rats and ca

141 , and ultra-sensitive detection of brain and spinal cord injury markers in bodily fluids is an unmet

142 Significance statement: Brain and spinal cord injury may lead to permanent disability and

143 early inflammatory response was observed in spinal cord injury mice characterized in lungs by a decr

144 Spinal cord injury mice were more susceptible to methici

145 on of neuroimaging biomarkers in centres for spinal cord injury might lead to personalised patient ca

146 growth and functional recovery in vivo in a spinal cord injury model through a unique mechanism of a

147 Inhibition of calmodulin in a rat spinal cord injury model with the licensed drug trifluop

148 nitor cells in vitro and host axons in a rat spinal cord injury model.

149 cystic cavities in a clinically relevant rat spinal cord injury model.

150 cystic cavities in a clinically relevant rat spinal cord injury model.

151 rapeutic siRhoA carrier in a rat compression spinal cord injury model.

152 veral neurological disorders such as stroke, spinal cord injury, multiple sclerosis, amyotrophic late

153 Traumatic spinal cord injury occurs when an external physical impa

154 Following spinal cord injury, oligodendrocyte loss and an inhibito

155 rs for the evaluation of injury severity for spinal cord injury or other forms of traumatic, acute, n

156 Upon testing clinical samples of spinal cord injury patients and healthy controls, both p

157 The ability to improve motor function in spinal cord injury patients by reactivating spinal centr

158 significant quality-of-life issues for many spinal cord injury patients.

159 er, patients with impaired voiding following spinal cord injury, patients undergoing nonurologic surg

160 on's disease, amyotrophic lateral sclerosis, spinal cord injury, peripheral neuropathy, and stroke.

161 nal cord after damage (e.g., after stroke or spinal cord injury), possibly assisting recovery of func

162 Spinal cord injury remains a scientific and therapeutic

163 Tissue repair after spinal cord injury requires the mobilization of immune a

164 cerebellar ataxia, Alzheimer's disease, and spinal cord injury, respectively.

165 us system (CNS) injuries, such as stroke and spinal cord injuries, result in the formation of a prote

166 s neurological conditions, such as stroke or spinal cord injury, result in an impaired control of the

167 Spinal cord injury results in locomotor impairment attri

168 Traumatic spinal cord injury results in severe and irreversible lo

169 ied in 384 patients with clinically complete spinal cord injury (SCI) and consequent anejaculation.

170 nctional paradox in the context of traumatic spinal cord injury (SCI) and discuss the underlying mech

171 othelial cells in engulfing myelin debris in spinal cord injury (SCI) and experimental autoimmune enc

172 ll (NSPC) grafts can integrate into sites of spinal cord injury (SCI) and generate neuronal relays ac

173 Loss of bladder control is common after spinal cord injury (SCI) and no causal therapies are ava

174 Respiratory complications in patients with spinal cord injury (SCI) are common and have a negative

175 Spasms after spinal cord injury (SCI) are debilitating involuntary mu

176 isms that regulate macrophage function after spinal cord injury (SCI) are poorly understood.

177 Spinal cord injury (SCI) at high spinal levels (e.g., ab

178 To investigate metabolic changes in chronic spinal cord injury (SCI) by applying MR spectroscopy in

179 Individuals with spinal cord injury (SCI) can face decades with permanent

180 More than half of spinal cord injury (SCI) cases occur in the cervical reg

181 Traumatic spinal cord injury (SCI) causes a cascade of degenerativ

182 Spinal cord injury (SCI) causes immune dysfunction, incr

183 Acute spinal cord injury (SCI) causes systemic immunosuppressi

184 After spinal cord injury (SCI) chronic inflammation hampers re

185 Spinal cord injury (SCI) disrupts critical physiological

186 didate cellular treatment approach for human spinal cord injury (SCI) due to their unique regenerativ

187 Axon regeneration after spinal cord injury (SCI) fails due to neuron-intrinsic m

188 Most studies targeting chronic spinal cord injury (SCI) have concluded that neural stem

189 eurotransplantation research to the clinical spinal cord injury (SCI) human population, and few studi

190 Spinal cord injury (SCI) impairs the flow of sensory and

191 t therapy promotes functional recovery after spinal cord injury (SCI) in animal and clinical studies.

192 nm pulse emission) on the spinal cord after spinal cord injury (SCI) in rats.

193 the loss of neuron-derived monoamines after spinal cord injury (SCI) in rats.

194 Spinal cord injury (SCI) induces a centralized fibrotic

195 Spinal cord injury (SCI) interrupts descending projectio

196 The inflammatory response to spinal cord injury (SCI) involves localization and activ

197 STATEMENT Pain sensitization associated with spinal cord injury (SCI) involves poorly understood mala

198 Spinal cord injury (SCI) is a common cause of disability

199 SCI tissue remodeling.SIGNIFICANCE STATEMENT Spinal cord injury (SCI) is characterized by formation o

200 Chronic pain caused by spinal cord injury (SCI) is notoriously resistant to tre

201 GNIFICANCE STATEMENT Chronic pain induced by spinal cord injury (SCI) is often permanent and debilita

202 The goal of stem cell therapy for spinal cord injury (SCI) is to restore motor function wi

203 Whether this ability is preserved after spinal cord injury (SCI) is unknown.

204 function or lesion pathology after traumatic spinal cord injury (SCI) is unknown.

205 or muscle injury, but the Acomys response to spinal cord injury (SCI) is unknown.

206 NS trauma and disease.SIGNIFICANCE STATEMENT Spinal cord injury (SCI) leads to profound functional de

207 Spinal cord injury (SCI) leads to wide-spread neurodegen

208 Spinal cord injury (SCI) lesions present diverse challen

209 sensory or serotonergic axons through severe spinal cord injury (SCI) lesions.

210 IGNIFICANCE STATEMENT Neuropathic pain after spinal cord injury (SCI) may in part be caused by upregu

211 Humans with cervical spinal cord injury (SCI) often recover voluntary control

212 e a full lower limb perceptual experience in spinal cord injury (SCI) patients, and will ultimately,

213 one of the most devastating forms of trauma, spinal cord injury (SCI) remains a challenging clinical

214 e timing of surgical decompression for acute spinal cord injury (SCI) remains debated, with substanti

215 Spinal cord injury (SCI) remains one of the biggest chal

216 Spinal cord injury (SCI) remains one of the most debilit

217 Traumatic primary spinal cord injury (SCI) results in paralysis below the

218 munity long after SCI.SIGNIFICANCE STATEMENT Spinal cord injury (SCI) significantly disrupts immunity

219 st common symptoms manifested in humans with spinal cord injury (SCI) to date, its mechanisms of acti

220 aralyzed muscles can be reanimated following spinal cord injury (SCI) using a brain-computer interfac

221 illions of patients suffer from debilitating spinal cord injury (SCI) without effective treatments.

222 c neuropathic pain is a major comorbidity of spinal cord injury (SCI), affecting up to 70-80% of pati

223 In this regard, spinal cord injury (SCI), Alzheimer's disease, and other

224 ays significance roles in recovery following spinal cord injury (SCI), and diabetes mellitus (DM) imp

225 functional recovery and neural repair after spinal cord injury (SCI), as well as axonal regeneration

226 Following spinal cord injury (SCI), astrocytes demonstrate long-la

227 Spontaneous remyelination occurs after spinal cord injury (SCI), but the extent of myelin repai

228 Microglia are activated after spinal cord injury (SCI), but their phagocytic mechanism

229 are killed for several weeks after traumatic spinal cord injury (SCI), but they are replaced by resid

230 In people or animals with incomplete spinal cord injury (SCI), changing a spinal reflex throu

231 Spasticity, a common complication after spinal cord injury (SCI), is frequently accompanied by c

232 After spinal cord injury (SCI), meningeal ILC2s are activated

233 Following spinal cord injury (SCI), newly formed endothelial cells

234 chanism of inflammation-regulation following spinal cord injury (SCI), orchestrated by CD200-ligand (

235 Months after spinal cord injury (SCI), respiratory deficits remain th

236 In spinal cord injury (SCI), the initial damage leads to a

237 Following spinal cord injury (SCI), the innate immune response of

238 influence many pathological processes after spinal cord injury (SCI), the intrinsic molecular mechan

239 In spinal cord injury (SCI), timely therapeutic interventio

240 Also, in rat T9-T10 hemisection spinal cord injury (SCI), we demonstrated that the tailo

241 esolution of inflammation is defective after spinal cord injury (SCI), which impairs tissue integrity

242 ical deficits and long-term disability after spinal cord injury (SCI).

243 subjects with neurogenic bladder (NB) due to spinal cord injury (SCI).

244 ethod to treat challenging diseases, such as spinal cord injury (SCI).

245 of a million individuals in the US live with spinal cord injury (SCI).

246 e commonly encountered in people living with spinal cord injury (SCI).

247 of bone mineral density (BMD) in people with Spinal Cord Injury (SCI).

248 st common symptoms manifested in humans with spinal cord injury (SCI).

249 f a spastic muscle in humans with incomplete spinal cord injury (SCI).

250 promotes recovery of function in humans with spinal cord injury (SCI).

251 measures in a preclinical model of traumatic spinal cord injury (SCI).

252 e (TG) was performed in persons with chronic spinal cord injury (SCI).

253 y associated with persistent pain induced by spinal cord injury (SCI).

254 examine their therapeutic potential to treat spinal cord injury (SCI).

255 cytes that protect tissue and function after spinal cord injury (SCI).

256 he recovery of hand motor function following spinal cord injury (SCI).

257 rious neurological pathologies and following spinal cord injury (SCI).

258 and impaired wound healing, as occurs after spinal cord injury (SCI).

259 d in humans with incomplete chronic cervical spinal cord injury (SCI).

260 the recovery of hand function in humans with spinal cord injury (SCI).

261 among the most challenging complications of spinal cord injury (SCI).

262 o improve locomotor function in the rat with spinal cord injury (SCI).

263 the potential to restore function following spinal cord injury (SCI).

264 subjects with neurogenic bladder (NB) due to spinal cord injury (SCI).

265 opment of chronic neuropathic pain following spinal cord injury (SCI).

266 paring in Bmal1(-/-) mice after T9 contusive spinal cord injury (SCI).

267 ioning sciatic nerve axotomy that precedes a spinal cord injury (SCI).

268 rly capable of plastic adaptations following spinal cord injury (SCI).

269 promotes functional recovery in humans with spinal cord injury (SCI).

270 oride extruder KCC2 lead to spasticity after spinal cord injury (SCI).

271 ndamental to reestablish motor control after spinal-cord injury (SCI).

272 c pain and loss of bladder control caused by spinal cord injuries (SCIs) can severely affect quality

273 mber of individuals with cervical incomplete spinal cord injury show limited functional recovery of e

274 ion in conditions such as cerebral palsy and spinal cord injury.SIGNIFICANCE STATEMENT Acquisition of

275 or stimulating axonal regeneration following spinal cord injury.SIGNIFICANCE STATEMENT Injury of peri

276 se data indicate that RN-NSCs grafted into a spinal cord injury site relay supraspinal control of ser

277 visors, urology, multiple sclerosis (MS) and spinal cord injury specialist nurses, and General Practi

278 In patients with spinal cord injury, spinal cord injury-immune depression

279 izes glial activation in an ex vivo model of spinal cord injury, suggesting a new strategy for spinal

280 After paralyzing spinal cord injury the adult nervous system has little a

281 c spinal cord injury (tSCI) and nontraumatic spinal cord injury - the most common form of which is de

282 After CNS trauma such as spinal cord injury, the ability of surviving neural elem

283 s system to restore motor function following spinal cord injury, the role of cortical targets remain

284 turnover to sustain axon regeneration after spinal cord injury through its actin-severing activity.

285 and preclinical research has used models of spinal cord injury to better elucidate the underlying me

286 Appropriate spinal cord injury treatment at individual centers.

287 Spinal cord MRI findings in traumatic spinal cord injury (tSCI) and nontraumatic spinal cord i

288 tients with acute, severe thoracic traumatic spinal cord injuries (TSCIs), American spinal injuries a

289 The study was then extended using GBS and spinal cord injury unrelated patients with similar medic

290 Here we characterized a porcine model of spinal cord injury using a combined behavioural, histolo

291 ipate in neuronal development, angiogenesis, spinal cord injury, viral invasion, and immune response.

292 As rats are used extensively to model spinal cord injury, we asked if the S1 CST response is c

293 Eight weeks post contusive spinal cord injury, we built a peripheral nerve graft br

294 normal muscle tone in awake female mice with spinal cord injuries were investigated.

295 ic incomplete cervical, thoracic, and lumbar spinal cord injury were randomly assigned to 10 sessions

296 l of the "engineered tissue" was assessed in spinal cord injuries, where hNSC-derived progenitors and

297 in individuals with chronic, motor complete spinal cord injury, which is a key achievement toward th

298 f an individual with traumatic high-cervical spinal cord injury who coordinated reaching and grasping

299 , it presents as a potential therapeutic for spinal cord injury with evidence for behavioural improve

300 PCMS without exercise in 13 individuals with spinal cord injury with similar characteristics.